Rajkumar Natarajan

Dr. Rajkumar Natarajan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2025 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
RNRajkumar Natarajan
Rajkumar Natarajan
NCNatasha Corballis
Natasha Corballis
IMIoannis Merinopoulos
Ioannis Merinopoulos
VTVasiliki Tsampasian
Vasiliki Tsampasian
VVVassilios S. Vassiliou
Vassilios S. Vassiliou
SESimon C. Eccleshall
Simon C. Eccleshall
Background: Modern contemporary percutaneous coronary intervention (PCI) techniques with drug-eluting stents (DES) have high procedural success rates in chronic total occlusion (CTO) but with a high prevalence of repeat revascularization. The use of drug-coated balloons (DCBs) in CTO is an alternative treatment strategy. The evidence for DCBs in CTO is, therefore, of interest, and we provide a structured and comprehensive review of the evidence available in terms of the use of DCBs in CTO, including de novo and in-stent (IS) CTO lesions. Objectives: We conducted a systematic review and meta-analysis on the use of DCBs in the management of coronary CTO. Methods: Electronic databases (PubMed, Embase and Ovid) were systematically searched from inception to April 2024 for DCB CTO studies. A meta-analysis was undertaken using a random-effects inverse-variance method due to heterogeneity. The primary outcome is target lesion revascularization (TLR). Secondary outcomes are major adverse cardiac events (MACE) as a composite of target lesion revascularization (TLR), cardiac death (CD), and any myocardial infarction (MI) including procedural and non-procedural MI, target vessel revascularization (TVR), angiographic outcomes such as late lumen loss (LLL), binary restenosis, and reocclusion. Results: A total of 10 studies consisting of 1,695 patients were systematically reviewed. This showed that late luminal changes in terms of lumen gain and minimal lumen loss were consistently seen in CTO cohorts 7–12 months after DCB treatment. Five studies were included for meta-analysis with 1,474 patients. There were no significant differences in TLR between treatment strategies such as DCB, DES, and hybrid (DES + DCB) in both de novo and IS-CTO populations as follows: DCB vs DES [OR, 0.71; 95% CI 0.49–1.02], DCB vs DES in IS-CTO [OR, 0.78; 95% CI 0.45–1.34], DCB vs Hybrid [OR, 0.96; 95% CI 0.39–1.43], and hybrid vs DES [OR, 0.76; 95% CI 0.15–3.84]. Similar findings were seen with the MACE outcome. A sensitivity analysis showed no difference between the above-mentioned groups in terms of MI, CD, and TVR. Conclusion: The limited initial evidence on DCB in coronary CTO-PCI suggests a safe and effective alternative treatment strategy and suggests RCTs are, therefore, required. Graphical

19 December 2024 in Heart International
Verified
Journal Article
Open access
PDF file
RNRajkumar Natarajan
Rajkumar Natarajan
NCNatasha Corballis
Natasha Corballis
IMIoannis Merinopoulos
Ioannis Merinopoulos
VVVassilios S Vassiliou
Vassilios S Vassiliou
SESimon C Eccleshall
Simon C Eccleshall
It has been recognized for decades that dissections occur as a mechanism of balloon angioplasty. A successful angioplasty result contains some degree of intimal splitting and disruption, which usually heals well. Nonetheless, some dissections are extensive, leading to serious ischaemic complications. The concept of therapeutic coronary dissection started evolving in the 1970s and seems to be a favourable mechanism for drug delivery in the current era of drug-coated balloons. This article will primarily focus on studies undertaken to understand the mechanism of balloon angioplasty and the morphological changes in the plaque post-balloon angioplasty. In the early days of balloon angioplasty, there was an enormous interest in dissections, mainly to prevent acute vessel closure events and to address the importance of their occurrence in relation to vessel restenosis. We will review the historical background, studies defining the clinical, angiographic and morphological patterns of the dissection spectrum and various currently evolving management strategies.

12 February 2026 in Clinical Research in Cardiology
Verified
Journal Article
Open access
RNRajkumar Natarajan
Rajkumar Natarajan
NCNatasha Corballis
Natasha Corballis
IMIoannis Merinopoulos
Ioannis Merinopoulos
TGTharusha Gunawardena
Tharusha Gunawardena
UWUpul Wickramarachchi
Upul Wickramarachchi
CMClint Maart
Clint Maart
Aim: The role of drug-coated balloon (DCB)–only strategy in de novo chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains uncertain. We compared DCB with drug-eluting stent (DES) strategies in patients undergoing CTO angioplasty. Methods: We retrospectively analyzed 170 patients with de novo CTO undergoing PCI between 2013 and 2019. Patients were treated with either DCB-only ( n = 85) or DES-only ( n = 85) strategies. The primary endpoint was target vessel revascularization (TVR); secondary endpoints included all-cause mortality, cardiovascular death, target vessel-myocardial infarction (TV-MI), any MI, and a composite of all-cause mortality, MI, and TVR. Median follow-up was 3.67 years. Results: TVR occurred in 11 (12.9%) DCB vs. 5 (5.9%) DES patients (HR 2.33, 95% CI 0.81–6.74, p = 0.118). All-cause mortality (7.1% vs. 12.9%; HR 0.56, p = 0.262) and the composite endpoint (21.2% vs. 20.0%; HR 1.15, p = 0.686) did not differ significantly. After adjustment for creatinine, J-CTO score, and vessel diameter, outcomes remained comparable between groups. Creatinine was independently associated with mortality and the composite endpoint. No acute vessel closure or thrombosis occurred within 30 days. During follow-up, no target lesion thrombosis was observed in the DCB group, while one late stent thrombosis (1.2%) occurred in the DES group. Conclusion: In this single-center study, a DCB-only strategy for de novo CTO PCI demonstrated long-term efficacy and safety outcomes comparable to DES, supporting DCB as a potential alternative. Graphical

26 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IMIoannis Merinopoulos
Ioannis Merinopoulos
NCNatasha Corballis
Natasha Corballis
UBU Bhalraam
U Bhalraam
RNRajkumar Natarajan
Rajkumar Natarajan
TGTharusha Gunawardena
Tharusha Gunawardena
SESimon Charles Eccleshall
Simon Charles Eccleshall
Background: There are limited data about the use of drug-coated balloon (DCB)-only angioplasty for multivessel coronary disease. Objectives: The aim of this study was to assess the safety and efficacy of DCB-only angioplasty as compared with second-generation drug-eluting stents (DESs) in patients undergoing multivessel angioplasty. Methods: We compared major adverse cardiovascular events (MACEs) in all patients undergoing multivessel angioplasty in our institution from 1 January 2015 until 15 November 2019, with either the DCB-only or DES-only strategy. The primary endpoint of our study was a MACE, including cardiovascular mortality, acute coronary syndrome, target lesion revascularisation, stroke, or major bleeding. Data were analysed using Cox regression models, Kaplan–Meier estimator plots, and propensity score matching. Results: A total of 159 consecutive patients treated with DCB-only angioplasty and 222 consecutive patients treated with DES-only angioplasty were identified. The majority of the vessels treated were large vessels (>3 mm). After a median follow-up of 4 years, a total of 52 (33%) patients in the DCB and 73 (33%) patients in the DES group encountered a MACE (p = 0.97). The results did not change following propensity score matching. On multivariate Cox regression analysis in the propensity score-matched cohort, atrial fibrillation [HR = 2.37, CI: (1.22–4.61), p = 0.011] and diabetes [HR = 1.71, CI: (1.13–2.60), p = 0.011] were the only independent adverse predictors of MACE. Conclusions: DCB-only angioplasty appears to be safe and efficient when compared to DES for multivessel angioplasty in terms of MACEs after a follow-up of 4 years.

Verified
Journal Article
Open access
PDF file
IMIoannis Merinopoulos
Ioannis Merinopoulos
UBU Bhalraam
U Bhalraam
TGTharusha Gunawardena
Tharusha Gunawardena
NCNatasha Corballis
Natasha Corballis
RNRajkumar Natarajan
Rajkumar Natarajan
SESimon Charles Eccleshall
Simon Charles Eccleshall
Background: There are no data regarding the outcomes of patients with stent thrombosis (ST) being treated with drug-coated balloon (DCB) angioplasty. Our aim was to compare the outcomes of patients with ST treated with DCB vs. a drug eluting stent (DES). Methods: In this registry analysis, we identified all patients treated for ST in our institution from June 2011 until November 2019. We excluded patients who died in the cath lab, patients with uncrossable lesions, and patients treated with thrombectomy only. Patient outcomes were obtained from Hospital Episodes Statistics from NHS England. The primary endpoint of this study was the composite of cardiovascular mortality, acute coronary syndrome, or target lesion revascularisation. The data were analysed with Cox regression and Kaplan–Meier estimator plots. Results: A total of 173 patients were identified; 92 treated with DCB-only, 36 with balloon angioplasty (BA), 26 with DES, and 19 with a combination of DES and DCB. We compared the outcomes of 92 patients with DCB versus 20 patients with DES, all of which had presented with late or very late ST. There was no difference between DCB and DES in terms of the primary endpoint (p = 0.06). Multivariate analysis identified diabetes (adverse) and the use of GPIIbIIIa inhibitor (favourable) as the only independent predictors of the primary endpoint. Implantation of a DES was independently associated with worse cardiovascular mortality. Conclusions: This is the first study assessing the outcomes of patients with ST treated with DCB only. It has demonstrated that DCBs are an attractive therapeutic option with a tendency towards favourable outcomes when compared to DESs.

1 January 2025 in Heart International
Verified
Journal Article
Open access
PDF file
RNRajkumar Natarajan
Rajkumar Natarajan
NCNatasha Corballis
Natasha Corballis
IMIoannis Merinopoulos
Ioannis Merinopoulos
VVVassilios S Vassiliou
Vassilios S Vassiliou
SESimon C Eccleshall
Simon C Eccleshall
The bailout stenting (BOS) rates due to coronary dissection range from 11 to 21%.2,4–11 The decision to perform BOS for certain degrees of angiographic